首页> 外国专利> PREVENTING HYALURONAN-MEDIATED TUMORIGENETIC MECHANISMS USING INTRONIC RNAS

PREVENTING HYALURONAN-MEDIATED TUMORIGENETIC MECHANISMS USING INTRONIC RNAS

机译:使用内含RNA预防透明质酸介导的透血性机制

摘要

Patterns of microRNA (miRNA) expression are correlated to the degrees of tumor cell differentiation in human prostate cancer. MiRNAs can complementarily bind to either oncogenes or tumor suppressor genes, resulting in targeted gene silencing and thus changes of cellular tumorigenecity. Using miRNA microarray analysis, 8 down-regulated and 3 up-regulated known miRNAs in androgen-independent human prostate cancer cell lines, such as LNCaP C4-2B and PC3, compared to those androgen-dependent cell lines, such as LNCaP and PC3-AR9 were consistently detected. Fluorescent in-situ hybridization assays in human prostate cancer tissue arrays containing sixty patients at different stages also showed the same miRNA expression patterns in hormone-refractory prostate carcinomas (HRPC) compared to androgen-sensitive non-cancerous prostate epithelium. In-vitro tumorigenecity assays using one of the identified miRNAs, mir-146a, were performed to provide validation of its function in prostate cancer. Gain-of-function transfection of mir-146a markedly suppressed its targeted ROCK1 gene expression in androgen-independent PC3 cells, consequently resulting in reduced cancer cell proliferation, invasion and metastasis to human bone marrow endothelial cell monolayers. Since ROCK1 is the key kinase for activating hyaluronan-mediated HRPC transformation in vivo and in PC3 cells, mir-146a should function as a tumor-suppressor gene in modulating the ROCK1-associated tumorigenecity.
机译:microRNA(miRNA)表达模式与人类前列腺癌中肿瘤细胞的分化程度相关。 MiRNA可以互补地结合至癌基因或抑癌基因,从而导致靶向基因沉默,从而改变细胞的致癌性。使用miRNA微阵列分析,与那些依赖雄激素的细胞系(例如LNCaP和PC3-)相比,不依赖雄激素的人前列腺癌细胞系(例如LNCaP C4-2B和PC3)中的8个下调和3个上调的已知miRNA。始终检测到AR9。与雄激素敏感的非癌性前列腺上皮相比,在包含六十名患者的不同阶段的人类前列腺癌组织阵列中的荧光原位杂交测定法也显示出在激素难治性前列腺癌(HRPC)中相同的miRNA表达模式。使用已鉴定的miRNA之一mir-146a进行了体外致癌性分析,以验证其在前列腺癌中的功能。 mir-146a的功能转染显着抑制了其在雄激素非依赖性PC3细胞中的靶向ROCK1基因表达,因此导致癌细胞增殖,侵袭和转移至人骨髓内皮细胞单层减少。由于ROCK1是在体内和PC3细胞中激活乙酰透明质酸介导的HRPC转化的关键激酶,因此mir-146a在调节ROCK1相关的致癌性中应作为抑癌基因。

著录项

  • 公开/公告号US2010298416A1

    专利类型

  • 公开/公告日2010-11-25

    原文格式PDF

  • 申请/专利权人 SHAO-YAO YING;SHI-LUNG LIN;

    申请/专利号US20080740334

  • 发明设计人 SHAO-YAO YING;SHI-LUNG LIN;

    申请日2008-10-29

  • 分类号C12Q1/68;A61K31/7105;

  • 国家 US

  • 入库时间 2022-08-21 18:12:44

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号